PURPOSE: A blood test to detect colon cancer at a preventable stage would represent a major advancement. We have previously identified colon cancer-specific markers using focused proteomics analysis of nuclear structural proteins. Two of these markers, colon cancer-specific antigen (CCSA)-3 and CCSA-4, have been developed into blood-based markers that are able to distinguish individuals with colorectal cancer from those without. CCSA-2 is a distinct novel colon cancer marker identified using focused proteomics. EXPERIMENTAL DESIGN: Using an indirect ELISA on serum samples obtained from two institutions, we evaluated CCSA-2 as a serum-based colon cancer marker. A total of 111 serum samples from individuals who underwent colonoscopy and were subsequently diagnosed as either being normal or having hyperplastic polyps, nonadvanced adenomas, advanced adenomas, and colorectal cancer were evaluated. A diverse control population that consisted of 125 serum samples was also included in this study. RESULTS: Receiver operating characteristic analyses were used to measure the sensitivity and specificity of CCSA-2. CCSA-2 at a cutoff of 10.8 mug/mL has overall specificity of 78.4% [95% confidence interval (95% CI), 67.3-87.1%] and sensitivity of 97.3% (95% CI, 85.8-99.5%) in separating individuals with advanced adenomas and colorectal cancer from normal, hyperplastic, and nonadvanced adenoma populations. The receiver operating characteristic curve for CCSA-2 has an area under the curve of 0.90 (95% CI, 0.83-0.95). CONCLUSION: Our initial study shows that CCSA-2 is a potential serum-based marker for colon cancer detection with high sensitivity and specificity.
PURPOSE: A blood test to detect colon cancer at a preventable stage would represent a major advancement. We have previously identified colon cancer-specific markers using focused proteomics analysis of nuclear structural proteins. Two of these markers, colon cancer-specific antigen (CCSA)-3 and CCSA-4, have been developed into blood-based markers that are able to distinguish individuals with colorectal cancer from those without. CCSA-2 is a distinct novel colon cancer marker identified using focused proteomics. EXPERIMENTAL DESIGN: Using an indirect ELISA on serum samples obtained from two institutions, we evaluated CCSA-2 as a serum-based colon cancer marker. A total of 111 serum samples from individuals who underwent colonoscopy and were subsequently diagnosed as either being normal or having hyperplastic polyps, nonadvanced adenomas, advanced adenomas, and colorectal cancer were evaluated. A diverse control population that consisted of 125 serum samples was also included in this study. RESULTS: Receiver operating characteristic analyses were used to measure the sensitivity and specificity of CCSA-2. CCSA-2 at a cutoff of 10.8 mug/mL has overall specificity of 78.4% [95% confidence interval (95% CI), 67.3-87.1%] and sensitivity of 97.3% (95% CI, 85.8-99.5%) in separating individuals with advanced adenomas and colorectal cancer from normal, hyperplastic, and nonadvanced adenoma populations. The receiver operating characteristic curve for CCSA-2 has an area under the curve of 0.90 (95% CI, 0.83-0.95). CONCLUSION: Our initial study shows that CCSA-2 is a potential serum-based marker for colon cancer detection with high sensitivity and specificity.
Authors: Robert A Smith; Vilma Cokkinides; Andrew C von Eschenbach; Bernard Levin; Carmel Cohen; Carolyn D Runowicz; Stephen Sener; Debbie Saslow; Harmon J Eyre Journal: CA Cancer J Clin Date: 2002 Jan-Feb Impact factor: 508.702
Authors: Gisela Brünagel; Barbara N Vietmeier; Anthony J Bauer; Robert E Schoen; Robert H Getzenberg Journal: Cancer Res Date: 2002-04-15 Impact factor: 12.701
Authors: Eddy S Leman; Robert E Schoen; Joel L Weissfeld; Grant W Cannon; Lori J Sokoll; Daniel W Chan; Robert H Getzenberg Journal: Cancer Res Date: 2007-06-15 Impact factor: 12.701
Authors: Robert E Schoen; Ahmed Magheli; Lori J Sokoll; Daniel W Chan; Robert H Getzenberg Journal: Clin Cancer Res Date: 2012-12-27 Impact factor: 12.531
Authors: Oscar J Cordero; Monica Imbernon; Loretta De Chiara; Vicenta S Martinez-Zorzano; Daniel Ayude; Maria Paez de la Cadena; F Javier Rodriguez-Berrocal Journal: World J Clin Oncol Date: 2011-06-10
Authors: Loretta De Chiara; Ana M Rodríguez-Piñeiro; Francisco J Rodríguez-Berrocal; Oscar J Cordero; David Martínez-Ares; María Páez de la Cadena Journal: BMC Cancer Date: 2010-06-28 Impact factor: 4.430
Authors: Gillian Higgins; Katherine M Roper; Irene J Watson; Fiona H Blackhall; William N Rom; Harvey I Pass; Justin F X Ainscough; Dawn Coverley Journal: Proc Natl Acad Sci U S A Date: 2012-10-16 Impact factor: 11.205
Authors: Ken Herrmann; Axel Walch; Benjamin Balluff; Marc Tänzer; Heinz Höfler; Bernd J Krause; Markus Schwaiger; Helmut Friess; Roland M Schmid; Matthias P A Ebert Journal: Nat Clin Pract Gastroenterol Hepatol Date: 2009-03